Please assess the completion status of the following clinical trial:

Trial Title: Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed Kaposi's sarcoma (KS) involving the following:~  * Skin~ * Lymph nodes (palpable disease only)~ * Oral cavity~* Must have ≥ 5 measurable, previously nonirradiated, cutaneous lesions that can be used as indicator lesions~* Must have 2 lesions ≥ 5 x 5 mm that are accessible for 4 mm punch biopsy~* Serologically confirmed HIV positivity~* Concurrent antiretroviral therapy required, except for patients who have exhausted all available treatment options~  * Must be on a stable dose for ≥ 4 weeks~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 3 months~* No other neoplasia requiring cytotoxic therapy~* Not pregnant or nursing~* Fertile patients must use effective barrier contraception during and for 3 months after completion of study treatment~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior anthracycline therapy~* At least 4 weeks since prior antineoplastic treatment for KS, including any of the following:~  * Chemotherapy (6 weeks for nitrosoureas or mitomycin C)~ * Radiotherapy~ * Local therapy~ * Biological therapy~ * Investigational therapy~* At least 60 days since prior local therapy of any KS indicator lesion unless lesion has clearly progressed since treatment~* No other concurrent investigational drugs, cytotoxic chemotherapy, or KS-specific treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- liposomal daunorubicin citrate (Type: EXPERIMENTAL): 40 mg/m2 Days 1 and 15 every 28 days x 3 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).